196 related articles for article (PubMed ID: 34377023)
1. The Antitumor Activity of CAR-T-PD1 Cells Enhanced by HPV16mE7-Pulsed and SOCS1-Silenced DCs in Cervical Cancer Models.
Zheng J; Huang J; Ma W; Yang W; Hu B
Cancer Manag Res; 2021; 13():6045-6053. PubMed ID: 34377023
[TBL] [Abstract][Full Text] [Related]
2. Combining MPDL3280A with adoptive cell immunotherapy exerts better antitumor effects against cervical cancer.
Zheng Y; Yang Y; Wu S; Zhu Y; Tang X; Liu X
Bioengineered; 2017 Jul; 8(4):367-373. PubMed ID: 27754760
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immunotherapeutic effect of modified HPV16 E7-pulsed dendritic cell vaccine by an adeno-shRNA-SOCS1 virus.
Zhu Y; Zheng Y; Mei L; Liu M; Li S; Xiao H; Zhu H; Wu S; Chen H; Huang L
Int J Oncol; 2013 Oct; 43(4):1151-9. PubMed ID: 23877655
[TBL] [Abstract][Full Text] [Related]
4. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
[TBL] [Abstract][Full Text] [Related]
5. The advantages of PD1 activating chimeric receptor (PD1-ACR) engineered lymphocytes for PDL1(+) cancer therapy.
Tang X; Li Q; Zhu Y; Zheng D; Dai J; Ni W; Wei J; Xue Y; Chen K; Hou W; Zhang C; Feng X; Liang Y
Am J Transl Res; 2015; 7(3):460-73. PubMed ID: 26045887
[TBL] [Abstract][Full Text] [Related]
6. Targeting and cytotoxicity of chimeric antigen receptor T cells grafted with PD1 extramembrane domain.
Zhang A; Wang S; Sun Y; Zhang Y; Zhao L; Yang Y; Zhang Y; Xu L; Lei Y; Du J; Chen H; Duan L; He M; Shi L; Liu L; Wang Q; Hu L; Zhang B
Exp Hematol Oncol; 2023 Sep; 12(1):85. PubMed ID: 37777797
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice.
Li T; Wang J
BMC Cancer; 2020 Jul; 20(1):678. PubMed ID: 32689954
[TBL] [Abstract][Full Text] [Related]
8. Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector.
Lee HJ; Hwang SJ; Jeong EH; Chang MH
J Microbiol; 2024 May; ():. PubMed ID: 38700775
[TBL] [Abstract][Full Text] [Related]
9. The Third Generation Anti-HER2 Chimeric Antigen Receptor Mouse T Cells Alone or Together With Anti-PD1 Antibody Inhibits the Growth of Mouse Breast Tumor Cells Expressing HER2
Li P; Yang L; Li T; Bin S; Sun B; Huang Y; Yang K; Shan D; Gu H; Li H
Front Oncol; 2020; 10():1143. PubMed ID: 32766150
[TBL] [Abstract][Full Text] [Related]
10. Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor.
Zhao J; Dong J; Deng C; Zhang Q; Sun S; Li H; Bai Y; Deng H
Oncoimmunology; 2023; 12(1):2265703. PubMed ID: 37808405
[TBL] [Abstract][Full Text] [Related]
11. Construction of PD1/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer.
Chen C; Gu YM; Zhang F; Zhang ZC; Zhang YT; He YD; Wang L; Zhou N; Tang FT; Liu HJ; Li YM
Oncoimmunology; 2021 Mar; 10(1):1901434. PubMed ID: 33854821
[TBL] [Abstract][Full Text] [Related]
12. Human T cells engineered to express a programmed death 1/28 costimulatory retargeting molecule display enhanced antitumor activity.
Ankri C; Shamalov K; Horovitz-Fried M; Mauer S; Cohen CJ
J Immunol; 2013 Oct; 191(8):4121-9. PubMed ID: 24026081
[TBL] [Abstract][Full Text] [Related]
13. Dendritic cells infected by Ad-sh-SOCS1 enhance cytokine-induced killer (CIK) cell immunotherapeutic efficacy in cervical cancer models.
Zheng Y; Hu B; Xie S; Chen X; Hu Y; Chen W; Li S; Hu B
Cytotherapy; 2017 May; 19(5):617-628. PubMed ID: 28215653
[TBL] [Abstract][Full Text] [Related]
14. Effects of epidermal growth factor receptor fusion protein on the cytotoxic activity of SOCS1-silenced dendritic cells in vitro.
Jiang Q; Wang X; Qian M; Chen D; Xu Y
Oncol Rep; 2018 Mar; 39(3):1306-1312. PubMed ID: 29286121
[TBL] [Abstract][Full Text] [Related]
15. A chimeric switch-receptor PD1-DAP10-41BB augments NK92-cell activation and killing for human lung Cancer H1299 Cell.
Zhi L; Yin M; Su X; Zhang Z; Lu H; Li M; Guo C; Niu Z; Zhang X; Zhu W
Biochem Biophys Res Commun; 2022 Apr; 600():94-100. PubMed ID: 35217362
[TBL] [Abstract][Full Text] [Related]
16. [Antitumor effects and mechanisms of a dendritic cell vaccine which silenced SOCS1 by siRNA, stimulated by OK-432 and pulsed with lysate of HepG2 cells].
Song HF; Zhou J; Pan K; Wang QJ; Wang H; Huang LX; Li YQ; Xia JC
Ai Zheng; 2008 Jul; 27(7):685-91. PubMed ID: 18606059
[TBL] [Abstract][Full Text] [Related]
17. Overcome trastuzumab resistance of breast cancer using anti-HER2 chimeric antigen receptor T cells and PD1 blockade.
Li H; Yuan W; Bin S; Wu G; Li P; Liu M; Yang J; Li X; Yang K; Gu H
Am J Cancer Res; 2020; 10(2):688-703. PubMed ID: 32195036
[TBL] [Abstract][Full Text] [Related]
18. Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity.
Li W; Guo L; Rathi P; Marinova E; Gao X; Wu MF; Liu H; Dotti G; Gottschalk S; Metelitsa LS; Heczey A
Hum Gene Ther; 2017 May; 28(5):437-448. PubMed ID: 27530312
[TBL] [Abstract][Full Text] [Related]
19. Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers.
Zuo S; Wen Y; Panha H; Dai G; Wang L; Ren X; Fu K
Mol Immunol; 2017 May; 85():293-304. PubMed ID: 28360017
[TBL] [Abstract][Full Text] [Related]
20. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
